{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:22Z","timestamp":1786980502921,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,9,17]],"date-time":"2008-09-17T00:00:00Z","timestamp":1221609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s10096-008-0628-x","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T11:54:00Z","timestamp":1221566040000},"page":"331-337","source":"Crossref","is-referenced-by-count":76,"title":["Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention"],"prefix":"10.1007","volume":"28","author":[{"given":"C.","family":"Garcia-Vidal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rodr\u00edguez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Teij\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rodr\u00edguez-Carballeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Lacasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,9,17]]},"reference":[{"key":"628_CR1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261\u20131265. doi: 10.1086\/383317","journal-title":"Clin Infect Dis"},{"key":"628_CR2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098\u20131104. doi: 10.1056\/NEJMoa011110","journal-title":"N Engl J Med"},{"key":"628_CR3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","volume":"84","author":"NF Crum","year":"2005","unstructured":"Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84:291\u2013302. doi: 10.1097\/01.md.0000180044.19285.9a","journal-title":"Medicine (Baltimore)"},{"key":"628_CR4","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR et al (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46:2294\u20132300. doi: 10.1002\/art.10529","journal-title":"Arthritis Rheum"},{"key":"628_CR5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0749-0704(02)00022-2","volume":"18","author":"SB Greenberg","year":"2002","unstructured":"Greenberg SB (2002) Infections in the immunocompromised rheumatologic patient. Crit Care Clin 18:931\u2013956. doi: 10.1016\/S0749-0704(02)00022-2","journal-title":"Crit Care Clin"},{"key":"628_CR6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1521-6942(02)00107-9","volume":"17","author":"G Cunnane","year":"2003","unstructured":"Cunnane G, Doran M, Bresnihan B (2003) Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 17:345\u2013363. doi: 10.1016\/S1521-6942(02)00107-9","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"628_CR7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1577-3566(07)75605-1","volume":"8","author":"C Garcia-Vidal","year":"2007","unstructured":"Garcia-Vidal C, Salavert M (2007) Artritis reumatoide y el tropismo infeccioso. Seminarios Fundacion Esp Reumatologia 8:68\u201387","journal-title":"Seminarios Fundacion Esp Reumatologia"},{"key":"628_CR8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/j.semarthrit.2003.10.003","volume":"33","author":"O Elkayam","year":"2004","unstructured":"Elkayam O, Caspi D, Reitblatt T et al (2004) The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33:283\u2013288. doi: 10.1053\/j.semarthrit.2003.10.003","journal-title":"Semin Arthritis Rheum"},{"key":"628_CR9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2005.036434","volume":"65","author":"I Fomin","year":"2006","unstructured":"Fomin I, Caspi D, Lavy V et al (2006) Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 65:191\u2013194. doi: 10.1136\/ard.2005.036434","journal-title":"Ann Rheum Dis"},{"key":"628_CR10","first-page":"952","volume":"34","author":"S Visvanathan","year":"2007","unstructured":"Visvanathan S, Keenan GF, Baker DG et al (2007) Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving Infliximab plus methotrexate or methotrexate alone. J Rheumatol 34:952\u2013957","journal-title":"J Rheumatol"},{"key":"628_CR11","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1016\/j.vaccine.2008.04.028","volume":"26","author":"LB Gelinck","year":"2008","unstructured":"Gelinck LB, van der Bijl AE, Visser LG et al (2008) Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine 26:3528\u20133533. doi: 10.1016\/j.vaccine.2008.04.028","journal-title":"Vaccine"},{"key":"628_CR12","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","volume":"50","author":"L Bergstrom","year":"2004","unstructured":"Bergstrom L, Yocum DE, Ampel NM et al (2004) Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 50:1959\u20131966. doi: 10.1002\/art.20454","journal-title":"Arthritis Rheum"},{"key":"628_CR13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA, Keystone EC, Menzies R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148\u2013155. doi: 10.1016\/S1473-3099(03)00545-0","journal-title":"Lancet Infect Dis"},{"key":"628_CR14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","volume":"2","author":"WS Mow","year":"2004","unstructured":"Mow WS, Abreu-Martin MT, Papadakis KA et al (2004) High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2:309\u2013313. doi: 10.1016\/S1542-3565(04)00060-6","journal-title":"Clin Gastroenterol Hepatol"},{"key":"628_CR15","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, G\u00f3mez-Reino JJ, Rodr\u00edguez-Valverde V et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766\u20131772. doi: 10.1002\/art.21043","journal-title":"Arthritis Rheum"},{"key":"628_CR16","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/ard.2007.069799","volume":"66","author":"J Sellam","year":"2007","unstructured":"Sellam J, Hamdi H, Roy C et al (2007) Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 66:1610\u20131615. doi: 10.1136\/ard.2007.069799","journal-title":"Ann Rheum Dis"},{"key":"628_CR17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/521107","volume":"45","author":"GH Mazurek","year":"2007","unstructured":"Mazurek GH, Weis SE, Moonan PK et al (2007) Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis 45:837\u2013845. doi: 10.1086\/521107","journal-title":"Clin Infect Dis"},{"key":"628_CR18","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1086\/521106","volume":"45","author":"GH Mazurek","year":"2007","unstructured":"Mazurek GH, Zajdowicz MJ, Hankinson AL et al (2007) Detection of Mycobacterium tuberculosis infection in United States navy recruits using the tuberculin skin test or whole-blood interferon-gamma release assays. Clin Infect Dis 45:826\u2013836. doi: 10.1086\/521106","journal-title":"Clin Infect Dis"},{"key":"628_CR19","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","volume":"53","author":"M Esteve","year":"2004","unstructured":"Esteve M, Saro C, Gonz\u00e1lez-Huix F et al (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn\u2019s disease patients: need for primary prophylaxis. Gut 53:1363\u20131365. doi: 10.1136\/gut.2004.040675","journal-title":"Gut"},{"key":"628_CR20","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/ibd.20202","volume":"13","author":"M Esteve","year":"2007","unstructured":"Esteve M, Loras C, Gonz\u00e1lez-Huix F (2007) Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn\u2019s disease patient. Inflamm Bowel Dis 13:1450\u20131451. doi: 10.1002\/ibd.20202","journal-title":"Inflamm Bowel Dis"},{"key":"628_CR21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1086\/427941","volume":"40","author":"C Garcia Vidal","year":"2005","unstructured":"Garcia Vidal C, Rodr\u00edguez Fern\u00e1ndez S, Mart\u00ednez Lacasa J et al (2005) Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40:756\u2013759. doi: 10.1086\/427941","journal-title":"Clin Infect Dis"},{"key":"628_CR22","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1086\/508538","volume":"43","author":"F Tubach","year":"2006","unstructured":"Tubach F, Ravaud P, Salmon-C\u00e9ron D et al (2006) Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonist. Clin Infect Dis 43:e95\u2013e100. doi: 10.1086\/508538","journal-title":"Clin Infect Dis"},{"key":"628_CR23","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"WG Dixon","year":"2006","unstructured":"Dixon WG, Watson K, Lunt M et al (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368\u20132376. doi: 10.1002\/art.21978","journal-title":"Arthritis Rheum"},{"key":"628_CR24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF02274842","volume":"10","author":"RJ Hine","year":"1990","unstructured":"Hine RJ, Everson MP, Hardin JM et al (1990) Methotrexate therapy in rheumatoid arthritis patients diminishes lectin-induced mononuclear cell proliferation. Rheumatol Int 10:165\u2013169. doi: 10.1007\/BF02274842","journal-title":"Rheumatol Int"},{"key":"628_CR25","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","volume":"362","author":"MS Lionakis","year":"2003","unstructured":"Lionakis MS, Kontoyiannis DP (2003) Glucocorticoids and invasive fungal infections. Lancet 362:1828\u20131838. doi: 10.1016\/S0140-6736(03)14904-5","journal-title":"Lancet"},{"key":"628_CR26","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJM198806023182203","volume":"318","author":"WJ McCune","year":"1988","unstructured":"McCune WJ, Golbus J, Zeldes W et al (1988) Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318:1423\u20131431","journal-title":"N Engl J Med"},{"key":"628_CR27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","volume":"13","author":"SL Schreiber","year":"1992","unstructured":"Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136\u2013142. doi: 10.1016\/0167-5699(92)90111-J","journal-title":"Immunol Today"},{"key":"628_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","volume":"55","author":"SS Jick","year":"2006","unstructured":"Jick SS, Lieberman ES, Rahman MU et al (2006) Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55:19\u201326. doi: 10.1002\/art.21705","journal-title":"Arthritis Rheum"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-008-0628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-008-0628-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-008-0628-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T05:34:11Z","timestamp":1559108051000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-008-0628-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,17]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["628"],"URL":"https:\/\/doi.org\/10.1007\/s10096-008-0628-x","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,17]]}}}